Save up -80% on Belimumab
Note: this is a drug discount program, not an insurance plan.
2018 Price of Belimumab
* price without discount in nearest pharmacy. Price may vary.
We offer free Belimumab coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your discount card in most local pharmacies to get a discount on Belimumab every time. What are you waiting for? Claim your prescription drug card now!
Belimumab volume of distribution
Vdss, 10 mg/kg, SLE patients = 5.29 L.
Discount Cards 16,000+
Clients Benefit 29%
Total savings $4,735,080
What is Belimumab
Belimumab is an intravenous immunosupressant for the adjunctive treatment of systemic lupus erythematosus (SLE). More specifically, it is a fully human recombinant IgG1 monoclonal antibody produced from a recombinant NS0 cell line stably transfected with the belimumab heavy chain and light chain genes. It is the first biological treatment approved for the indication of SLE. Concomitant use with live or inactivated vaccines must be avoided. Belimumab was FDA approved on March 9, 2011. Belimumab consists of 2 heavy chains, and 2 light chains of the lambda subclass. Each heavy chain contains 452 amino acid residues and each light chain contains 214 amino acid residues. There are 3 post-translational modifications: a conserved N-linked glycosylation on the CH2 domain at Asn 303 of the heavy chain, the conversion of the N-terminal glutamine residue of the heavy chain into pyroglutamate, and loss of C-terminal lysine residue of the heavy chain.
Belimumab mechanism of action
Belimumab selectively binds to soluble human B lymphocyte stimulator protein (BLyS) so that BLyS is unable to bind to receptors on B lymphocytes. The binding of BLyS to its receptor is essential for the survival of B lymphocytes. Consequently, belimumab reduces B-cell mediated immunity and the autoimmune response.
Dosage forms of Belimumab
|Injection, powder, lyophilized, for solution||intravenous||120 mg/1.5mL|
|Injection, powder, lyophilized, for solution||intravenous||400 mg/5mL|
|Powder for concentrate for solution for infusion||Intravenous use||120 mg|
Human Genome Sciences, Inc.
Humans and other mammals
Indication of Belimumab
Adjunct treatment for auto-antibody-positive active systemic lupus erythematosus.
Toxicity of Belimumab
The most commonly-reported adverse reactions, occurring in 5% of patients in clinical trials were nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, and pharyngitis. The most common serious adverse reactions were serious infections.
RX24 Drugs Disclaimer: before buying a Belimumab on prescription, consult your healthcare provider. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.